NextCure (NXTC) Metrics: History & Chart

NextCure, Inc.(NXTC)

Biotechnology · Beltsville, MD

$5.38+0.33 (+6.62%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

About NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

Beltsville, MD

40 employees

www.nextcure.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael S. Richman

View full financials

Third-Party DCF Estimate (FMP)	$6.72
Price Gap vs Third-Party Estimate	+28.89%

7D Total Return	-0.59%
30D Total Return	-35.42%
YTD Total Return	-64.41%
1Y Total Return	-13.53%
3Y Total Return	-66.60%
5Y Total Return	-94.63%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-64.41%
2025	+53.41%
2024	-32.38%
2023	-19.15%
2022	-76.50%
2021	-44.95%
2020

CAGR TTM	-13.47%
CAGR 3Y	-30.61%
CAGR 5Y	-44.29%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

NXTC Valuation Metrics

NXTC Stock Price Metrics

NXTC Dividend Metrics

NXTC Growth Rate Metrics

NXTC Discounted Cash Flow Metrics

NXTC Returns By Period

NXTC Yearly Returns

NXTC Average Annual Returns By Period (CAGR)

NXTC Revenue Metrics

NXTC PE Ratio Metrics

NXTC PS Ratio Metrics

NXTC PB Ratio Metrics

NXTC Price to Free Cash Flow Ratio Metrics

NXTC Debt to Equity Ratio Metrics

NXTC PEG Ratio Metrics

NXTC FCF Yield

NXTC Earnings Yield

NXTC EBITDA Yield

NXTC OCF Yield

NXTC EV/EBIT Ratio Metrics

NXTC EV/EBITDA Ratio Metrics

NXTC EV/Assets Ratio Metrics

NXTC EV/Sales Ratio Metrics

NXTC Current Ratio Metrics

NXTC Quick Ratio Metrics

NXTC ROIC Metrics

NXTC Return on Assets Metrics

NXTC Return on Equity Metrics

NXTC Net Profit Margin Metrics

NXTC Gross Profit Margin Metrics

NXTC Tax Rate Metrics

PS Ratio	9.68
PS Ratio Avg TTM	11.99
PS Ratio Avg 3Y	112.90
Current VS TTM Avg	-19.25%
Current VS 3Y Avg	-91.43%
Current VS 5Y Avg	-91.43%

PB Ratio	2.21
PB Ratio Avg TTM	1.16
PB Ratio Avg 3Y	0.56
Current VS TTM Avg	+90.84%
Current VS 3Y Avg	+292.35%
Current VS 5Y Avg	+412.06%

PFCF Ratio	252.34
PFCF Ratio Avg TTM	278.20
PFCF Ratio Avg 3Y	278.20
Current VS TTM Avg	-9.29%
Current VS 3Y Avg	-9.29%
Current VS 5Y Avg	-9.29%

Debt/Equity Ratio	0.35
Debt/Equity Ratio Avg TTM	0.21
Debt/Equity Ratio Avg 3Y	0.11
Current VS TTM Avg	+67.56%
Current VS 3Y Avg	+235.20%
Current VS 5Y Avg	+417.88%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	0.40%
FCF Yield Avg TTM	0.44%
FCF Yield Avg 3Y	0.44%
Current VS TTM Avg	-8.93%
Current VS 3Y Avg	-8.93%
Current VS 5Y Avg	-8.93%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.70
Ev/Assets Ratio Avg TTM	0.63
Ev/Assets Ratio Avg 3Y	0.33
Current VS TTM Avg	+11.34%
Current VS 3Y Avg	+111.15%
Current VS 5Y Avg	+116.81%

Ev/Sales Ratio	8.37
Ev/Sales Ratio Avg TTM	11.09
Ev/Sales Ratio Avg 3Y	94.54
Current VS TTM Avg	-24.50%
Current VS 3Y Avg	-91.15%
Current VS 5Y Avg	-91.15%

Current Ratio	3.47
Current Ratio Avg TTM	3.78
Current Ratio Avg 3Y	9.01
Current VS TTM Avg	-8.18%
Current VS 3Y Avg	-61.50%
Current VS 5Y Avg	-79.34%

Quick Ratio	3.47
Quick Ratio Avg TTM	3.78
Quick Ratio Avg 3Y	9.01
Current VS TTM Avg	-8.18%
Current VS 3Y Avg	-61.50%
Current VS 5Y Avg	-79.34%

ROIC	(259.91%)
ROIC Avg 3Y	(115.30%)
ROIC Avg 5Y	(57.05%)
Current VS 3Y Avg	-125.42%
Current VS 5Y Avg	-355.62%
Current VS 10Y Avg	-531.22%

ROA	(188.98%)
ROA Avg TTM	(37.68%)
ROA Avg 3Y	(15.72%)
Current VS TTM Avg	-401.49%
Current VS 3Y Avg	-1102.50%
Current VS 5Y Avg	-1394.69%

ROE	(351.86%)
ROE Avg TTM	(230.83%)
ROE Avg 3Y	(130.66%)
Current VS TTM Avg	-52.43%
Current VS 3Y Avg	-169.28%
Current VS 5Y Avg	-504.78%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A